ライフサイエンスコーパス: reactivator

1 246) is a first-in-class, small-molecule p53 reactivator.

2 on of a promising, novel CNS-permeable oxime reactivator.

3 reported mechanism of action as a mutant-p53 reactivator.

4 t charge as potential central nervous system reactivators.

5 apy to combat OP poisoning involves an oxime reactivator (2-PAM, obidoxime, TMB4, or HI-6) combined w

6 ata identify NSC319726 as a p53(R175) mutant reactivator and as a lead compound for p53-targeted drug

7 re that, on one end makes them very powerful reactivators and on the other renders them ineffective a

8 activity relationships of this new family of reactivators and shows that 1b-d are uncharged hAChE rea

9 Better reactivators are sought, but their design is hampered by

10 ts mutant 17DeltaPst(LAT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

11 vator) or 17DeltaPst(LAT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

12 ed reactivation of the HSV-1 high phenotypic reactivator can upregulate gene expression involved in B

13 tion of KSHV by use of a small amount of the reactivator (doxycycline) more effective and enhanced vi

14 nhibition could be observed with HI-6 as the reactivator due to the extreme lability of the phosphory

15 nd carcinomas were hypersensitive to the p53 reactivator eprenetapopt (APR-246) relative to telomeras

16 ree yeast kinase families, nitrogen permease reactivator/halotolerance-5), polyamine transport kinase

17 is of acetylthiocholine reveal that distinct reactivator ionization states are involved in the reacti

18 awback of these charged acetylcholinesterase reactivators is their poor ability to cross the blood-br

19 poor nitrogen medium, the nitrogen permease reactivator kinase (Npr1) inhibits TORC1 activity and al

20 c property of the oximate anion, some of the reactivators may carry an accelerating determinant, as c

21 (2)), is superior to the reference uncharged reactivators monoisonitrosoacetone and 2,3-butanedione m

22 sis of X-ray structures of a CNS-penetrating reactivator, monoxime RS194B, reversibly bound to native

23 kinetics of the lead hydroxyimino acetamide reactivator of hAChE, when analyzed in terms of apparent

24 fficient than 2-PAM (up to 29000 times) as a reactivator of S(P)-phosphonates (k(r) ranged from 50 to

25 Recently, a new class of reactivators of chemical warfare agent inhibited acetylc

26 thesis and activity of a new series of oxime reactivators of cholinesterases (ChEs) that contain tert

27 r structural refinement into three efficient reactivators of human butyrylcholinesterase (hBChE) inhi

28 o develop reversible inhibitors of AChE into reactivators of nerve agent-inhibited AChE.

29 A new class of amidine-oxime reactivators of organophosphate (OP)-inhibited cholinest

30 bstituted 2-hydroxyiminoacetamido alkylamine reactivators of phosphylated human acetylcholinesterase

31 Small-molecule reactivators of PP2A (SMAP) inhibited CIP2A transcriptio

32 points away from the VX-bound serine) in the reactivator-only complex to a "semi-productive" orientat

33 with either HSV-1 17Syn(+) (high phenotypic reactivator) or 17DeltaPst(LAT(-)) (low phenotypic react

34 culated with HSV-1 17Syn(+) (high phenotypic reactivator) or its mutant 17DeltaPst(LAT(-)) (low pheno

35 onylated hAChE with an imidazole-based oxime reactivator, RS-170B.

36 One of the reactivators showed improved in vivo efficacy compared t

37 tently infected with either the low- or high-reactivator strains.

38 )MMF(-) EBV reactivators, the 9 DZB(+)MMF(+) reactivators tended to have more prolonged viremia (11.4

39 Current antidotes, including oxime reactivators that attack the OP-AChE conjugate to free t

40 Compared with 7 DZB(-)MMF(-) EBV reactivators, the 9 DZB(+)MMF(+) reactivators tended to

41 nical view of eprenetapopt from a mutant-p53 reactivator to a ferroptosis inducer.

42 rrent therapy includes a pyridinium aldoxime reactivator to restore the enzymatic activity of acetylc

43 ated species at physiological pH enables the reactivators to cross the blood-brain barrier and distri

44 s need to include much better access of AChE reactivators to the CNS and optimized orientation of the

45 A small library of imidazole and imidazolium reactivators was successfully synthesized using this met

46 tors and shows that 1b-d are uncharged hAChE reactivators with a broad spectrum.